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INTRODUCTION
WHILE HEPATOCYTE TRANSPLANTATION has been sug-gested as a promising strategy to treat some liver
diseases and alleviate organ donor shortage, the success
of this approach has been severely limited by the death
of a majority of the transplanted cells.1,2 Previous work
has indicated that insufficient vascularization of the con-
struct utilized for hepatocyte delivery is an important fac-
tor contributing to the loss of transplanted hepatocyte
populations.3 However, speeding vascularization of the
implants via vascular endothelial growth factor (VEGF)
delivery resulted in only a transient increase in hepato-
cyte survival, suggesting that the cells require additional
factors to promote longer-term survival.
Factors present in the portal circulation have a posi-
tive impact on the survival of transplanted hepatocytes,
as hepatocytes exhibit significantly increased survival
rates when transplanted into animals in which the portal
vein is shunted to the vena cava (portal caval shunt) such
that blood intended for the liver is redirected to the sys-
temic circulation.4–7 A combination of portal caval shunt-
ing and partial hepatectomy has also been demonstrated
to enhance transplanted hepatocyte engraftment,6 as sig-
nals promoting hepatocyte proliferation are likely pres-
ent in higher concentrations following partial hepatec-
tomy.8 While some of the factors present in the portal
circulation that promote hepatocyte survival and/or pro-
liferation likely remain to be discovered, several growth
factors and hormones important in these processes have
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Tissue engineering approaches have been investigated as a strategy for hepatocyte transplantation;
however the death of a majority of transplanted cells critically limits success of these approaches.
In a previous study, a transient increase in hepatocyte survival was achieved through delivery of
vascular endothelial growth factor (VEGF) from the porous polymer scaffold utilized for cell de-
livery. To enhance longer-term survival of the hepatocytes, this delivery system was modified to ad-
ditionally deliver epidermal growth factor (EGF) and hepatocyte growth factor (HGF) in a sus-
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engraftment was not improved, as survival declined to the level of control conditions for all growth
factor combinations after two weeks. This investigation indicates that the survival of hepatocytes
transplanted into heterotopic locations is dependent on multiple signals. The delivery system de-
veloped for the current study may be useful in elucidating the specific factors controlling this pro-
cess, and bring therapeutic transplantation of hepatocytes closer to implementation.
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been identified. Two growth factors that have been dem-
onstrated to play a key role in liver regeneration are epi-
dermal growth factor (EGF) and hepatocyte growth fac-
tor (HGF).9–12 Both EGF and HGF are also known to
promote the survival and proliferation of hepatocytes in
culture13,14 and have been shown to effect transplanted
hepatocyte survival.4,15,16
It was therefore hypothesized that sustained delivery
of EGF and HGF might promote longer-term survival of
transplanted hepatocytes. To investigate this hypothesis,
a polylactide-co-glycolide scaffold system previously de-
veloped to deliver VEGF was used to deliver EGF and
HGF additionally. The scaffold fabrication procedure
was first modified to release EGF and HGF in a sustained
manner throughout the planned study timeframe. In vitro
characterization of the scaffolds was then performed to
confirm that the released growth factors retained bioac-
tivity. Finally, hepatocytes were transplanted into subcu-
taneous tissue using scaffolds containing various combi-
nations of VEGF, EGF, and HGF to determine whether
inclusion of the hepatotrophic factors would promote
longer-term survival of the transplanted cells.
MATERIALS AND METHODS
Scaffold fabrication
Scaffolds were formed using a modification of a pre-
viously published process,17,18 which involves fabricat-
ing polylactide-co-glycolide (PLG) into microspheres
prior to forming scaffolds from the microspheres. Mi-
crospheres were fabricated from 85:15 (Medisorb,
Alkermes, Cambridge, MA) or 75:25 PLG (RG752,
Boehringer-Ingleheim, Ingleheim, Germany) via a stan-
dard double emulsion process.19 In brief, a 5% (w/v) so-
lution of PLG in ethyl acetate (EtAc) (Sigma, St. Louis,
MO) was combined with distilled, deionized water in a
test tube. In conditions using 75:25 PLG microspheres to
encapsulate EGF, lyophilized murine EGF (Peprotech,
Rocky Hill, NJ) was reconstituted in the water used as
the aqueous phase. This two-phase mixture was then son-
icated to yield a single emulsion. An equal volume of an
aqueous solution containing 1% polyvinyl alcohol (PVA,
MW 25,000, 88% hydrolyzed; Polysciences, Warrington,
PA) and 7% EtAc was added to the single emulsion, and
the resulting solution was vortexed (Vortex Genie, VWR
International, West Chester, PA) to yield the double
emulsion. This double emulsion was immediately trans-
ferred to a rapidly stirring aqueous solution of 0.3%
PVA/7% EtAc. After allowing the EtAc to evaporate for
3 h, the microsphere-containing solution was filtered to
retrieve the microspheres, which were then rinsed with
distilled water, flash frozen, and lyophilized.
For each scaffold, 4 mg of 75:25 PLG microspheres
and 16 mg of 85:15 PLG microspheres were combined
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with 100 L of 1% MVM alginate (FMC Biopolymer,
Philadelphia, PA) solution. When VEGF and/or HGF
were included in the scaffolds, 40 g recombinant hu-
man VEGF (R&D Systems, Minneapolis, MN) and/or 40
g of recombinant human HGF (Research Diagnostics,
Flanders, NJ) were dissolved in the alginate solution. In
conditions where EGF was included, the 75:25 PLG mi-
crospheres were fabricated to contain this growth factor,
as described above. All growth factors were omitted from
the fabrication process for conditions requiring blank
scaffolds. The desired microsphere/alginate/growth fac-
tor mixture was next lyophilized to form a powder, com-
bined with 380 mg NaCl (sieved to yield a particle di-
ameter between 250 and 425 m), and pressed into a 13
mm diameter die to create a 1.5 mm thick disk. The PLG
was gas foamed by subjecting the disks to 800 psi CO2
for 24 h, followed by a rapid reduction of pressure to am-
bient. The NaCl was leached from scaffolds by incubat-
ing in 0.1 M CaCl2 for 16 h prior to use in experiments.
Upon removal from the leach solution, each scaffold was
flash-frozen in liquid nitrogen and cut into quarters us-
ing a razor blade, and these quarter scaffolds were used
in all experiments. Scaffolds for determining growth fac-
tor release kinetics and bioactivity were fabricated to con-
tain 0.8 g EGF or 3.6 g HGF each, and scaffolds for
in vivo experiments were fabricated to contain 3.6 g
VEGF and 1.3 g EGF and/or 3.6 g HGF. In studies
where scaffolds were incubated with cells or implanted
into mice, they were soaked in 100% ethanol for 20 min,
followed by five 5 min washes with sterile phosphate
buffered saline (PBS) prior to cell seeding.
EGF and HGF release kinetics
To monitor the incorporation efficiency and release ki-
netics of EGF from the porous scaffolds, receptor grade
125I-labeled recombinant human EGF (ICN Biomedical,
Irvine, CA) was used as a tracer. When fabricating the
EGF-containing microspheres for this portion of the
study, 3 Ci radiolabeled EGF and 300 g unlabeled
EGF were dissolved in the aqueous phase added to the
polymer solution, as described above. A sample of this
aqueous solution was measured using a gamma counter
to determine the radioactivity added to each batch of mi-
crospheres. After microsphere fabrication and lyophiliza-
tion were complete, the radioactivity of a known mass of
microspheres was measured in the gamma counter and
compared to the radioactivity initially added to the total
polymer mass for the batch to assess incorporation effi-
ciency into the microspheres. Scaffolds were then made
according to the method described previously. After com-
pleting the gas foaming process but before leaching the
NaCl from scaffolds, the radioactivity present in each
scaffold was measured. After leaching, each scaffold was
again analyzed with the gamma counter to determine the
amount of protein remaining in the scaffolds. Next, scaf-
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folds were cut into quarters, which were each placed in
3 mL PBS (Gibco, Carlsbad, CA) with 0.132 g/L CaCl2-
2H2O and 0.10 g/L MgCl2-6H2O added. Scaffolds were
maintained in PBS at 37°C and at various times, a 1 mL
sample of the PBS was removed for measurement with
the gamma counter, and the remaining PBS was aspirated
and replaced with 3 mL of fresh PBS. The quantity of
EGF that had been released at each time point was de-
termined by comparing the radioactivity of the PBS sam-
ples to the total incorporation, as measured prior to ini-
tiating the release study.
The incorporation efficiency and release kinetics of
HGF were determined using a human HGF ELISA kit
(R&D Systems). Scaffolds for this part of the study were
fabricated to contain only HGF, as specified in the pre-
vious section, and samples of the leached solution were
reserved to measure the amount of growth factor lost in
this step and determine the incorporation efficiency. To
monitor HGF release, scaffolds were incubated in 2 mL
of PBS solution, as described above, and maintained at
37°C. At various times the PBS was removed, reserved
for analysis, and replaced with 2 mL of fresh PBS. The
ELISA was performed according to the kit instructions
in 96-well plates using 50 L of each sample or HGF
standard. Immediately following completion of the final
step of the ELISA, the optical density of each well was
measured using a microplate reader to determine the
amount of HGF in the samples. Finally, calculations were
performed to determine the amount of HGF released from
the scaffolds at each time point.
Bioactivity of released EGF and HGF
To assess the mitogenic potential of EGF and HGF that
had been incorporated into scaffolds, a fibroblast cell line
(NIH-3T3) and lung endothelial cells (4MBr-5) (both
from ATCC, Manassas, VA) were incubated with scaf-
folds releasing only EGF or HGF, respectively. EGF-con-
taining scaffolds were fabricated as described using mi-
crospheres of 75:25 PLG, with 300 g EGF added to the
aqueous phase during processing. Scaffolds containing
only HGF were also made according to the method out-
lined above.
The biological activity of released EGF or HGF was
confirmed by placing the scaffolds (n  5), supported in
transwells (12 mm, 3 m pore diameter), directly over
NIH-3T3 or 4MBr-5 cells growing in culture wells of a
12-well plate (Corning, Cambridge, MA) with 2 mL of
medium. NIH-3T3 cells were allowed to attach to culture
wells for 4 h in DMEM (Gibco) containing 2% FBS
(Gibco). Following the attachment period, the culture
medium was exchanged for serum-free DMEM, and tran-
swells containing scaffolds were placed in each well.
4MBr-5 cells were allowed to attach to the culture plate
overnight in Ham’s F12K medium (ATCC) with 10%
FBS, and serum was reduced to 2% prior to adding scaf-
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folds. In both studies, the cells were cultured in the pres-
ence of scaffolds for 72 h before cell number was de-
termined using a Coulter counter (Beckman-Coulter,
Fullerton, CA). The scaffolds in transwells were then
moved to wells freshly seeded, as described for each con-
dition, and allowed to incubate for an additional 72 h.
The magnitude of growth stimulation was compared to
control conditions where cells were cultured in the pres-
ence of scaffolds containing no growth factor and with
known concentrations of EGF (0.1–10 ng/mL) or HGF
(0.5–20 ng/mL).
Hepatocyte isolation
Hepatocytes were isolated from adult male Lewis rats
(150–200 g, Charles River Breeding Laboratories, Wilm-
ington, MA) with a modification of the original Seglen
two-step collagenase perfusion procedure.20 Briefly, the
liver was perfused via the portal vein, first with calcium-
free buffer (142 mM NaCl, 7 mM KCl, 20 mM Hepes,
pH 7.4, 37°C) for 10 min, followed immediately by col-
lagenase-containing buffer (142 mM NaCl, 7 mM KCl,
20 mM CaCl2, 20 mM Hepes, 0.5 mg/mL collagenase
type 2 [Worthington Biochemical, Lakewood, NJ] pH
7.4, 37°C). Perfusion with the collagenase-containing
buffer was continued for 7–10 min. The perfused liver
was then placed in ice-cold William’s Medium E (Gibco),
and cells were dissociated by removing the liver capsule
and gently shaking the hepatocytes free from the re-
maining liver matrix. This cell suspension was filtered
through a 400 m Nytex mesh (Tetko, Elmsford, NY) to
remove large debris. The cell yield per liver was 1–2 
108, and the initial percentage of viable cells was
80–90%. To further purify the cell population and remove
cellular debris, density gradient centrifugation using Per-
coll (Sigma) was performed. The collected hepatocytes,
which had a total cell viability of 90%, were then placed
on ice and immediately used in experiments.
SCID mouse implants
For the implant study, scaffolds were fabricated with
three different growth factor combinations: 1) VEGF and
EGF, 2) VEGF and HGF, and 3) VEGF, EGF, and HGF.
The EGF-containing microspheres for this study were
fabricated with a larger quantity of EGF (500 g per
batch) in an effort to better promote hepatocyte survival.
To make scaffolds, 4 mg of these EGF-microspheres or
blank 75:25 PLG microspheres were combined with 16
mg of 85:15 PLG microspheres, and VEGF and HGF
were incorporated as described previously. Immediately
before scaffold implantation, 1  106 hepatocytes were
suspended in 30 L of 1:1 mixture of William’s Medium
E and growth factor reduced Matrigel (BD Biosciences,
Bedford, MA), which was included to help retain cells
within the scaffolds, and allowed to absorb into the poly-
mer scaffold for 5 min. The cell-seeding efficiency was
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determined by counting the cells remaining in the dish
after this absorption period.
Scaffolds (n  4) from each condition were then im-
planted in subcutaneous pockets (2 per animal) on the
dorsal region of 7- to 9-week-old male SCID mice
(cb17/SCID, Taconic Labs, Germantown, NY). A 1.5 cm
longitudinal incision was made on the animal’s back, and
one implant was then placed on either side of the inci-
sion. The incision was then closed with VetBond tissue
adhesive (3M, St. Paul, MN). All NIH guidelines for the
care and use of laboratory animals (NIH Publication #85-
23, rev. 1985) were observed.
Mice were sacrificed and scaffolds retrieved at 3, 7,
and 14 days following implantation. The scaffolds were
dissected out of the tissue and immediately placed into
10 mL of buffered zinc-formalin, where they remained
for 24 h at 4°C. The zinc-formalin was then exchanged
for 70% ethanol, and samples were stored at 4°C until
they were embedded in paraffin by the University of
Michigan School of Dentistry Histology Core.
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FIG. 1. EGF release from PLG scaffolds. Values represent
mean and standard deviation (n  6).
FIG. 2. EGF (A) and HGF (C) released from scaffolds exhibit maintenance of biological activity in vitro, as compared with
cells’ response to known quantities of EGF (B) and HGF (D). (A and C) Cells were incubated with scaffolds releasing either
EGF or HGF and their proliferation was compared to that of cells incubated with blank scaffolds (n  5). (B and D) Cells were
cultured with a range of growth factor concentrations for 3 days (n  3).
Histological staining and analysis
The paraffin-embedded scaffolds were cut into 5 m
thick sections and placed on glass slides for histological
analysis. The University of Michigan Comprehensive
Cancer Center Histology Core performed the immuno-
histochemical staining for mouse CD31 antigen to iden-
tify endothelial cells present in the vasculature. To visu-
alize overall tissue morphology and distinguish surviving
hepatocytes, other sections were stained with hema-
toxylin and eosin.
Tissue sections were visualized and photographed
with an E-800 light microscope (Nikon, Melville, NY).
Four samples from each condition, with 3 sections from
each sample, were analyzed manually and digitally with
ImagePro Plus software (Media Cybernetics, San Diego
CA). Blood vessels present in implants retrieved at 7
and 14 days were analyzed for their total number and
were identified, at 200  magnification, by their de-
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fined lumens in sections stained for mouse CD31 anti-
gen. For implants retrieved at 3, 7, and 14 days, the to-
tal number of engrafted hepatocytes in each section 
was manually counted at 200  magnification. En-
grafted hepatocytes were identified by their large size,
distinct cytoplasmic staining, and large, spherical nu-
clei, while dead hepatocytes were identified by their
lack of a nucleus, as described in a number of published 
reports.2,21,22
Statistical analysis
The Student’s t test (one-tailed) was employed to de-
termine the statistical significance of differences between
data from growth factor and control conditions for both
engrafted hepatocyte and blood vessel quantification,
with p  0.05 considered significant. InStat software
(Version 2.01, GraphPad Software, San Diego, CA) was
used to perform this analysis.
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FIG. 3. H&E-stained sections of transplanted scaffolds containing hepatocytes. Hepatocytes were seeded onto matrices, im-
planted into SCID mice, and retrieved after 3, 7, and 14 days. Scaffold conditions not shown (VEGF  EGF and VEGF  HGF)
were both similar in appearance to the condition including all three factors. original magnification  400
RESULTS
Growth factor incorporation and release
The incorporation efficiency and release kinetics of
EGF from constructs were monitored using 125I labeled
EGF as a tracer. Analysis revealed that 25  2% of the
EGF added during processing remained in the micro-
spheres when fabrication was complete, which yielded
1.5 g EGF/mg microspheres. When scaffolds were fab-
ricated using these microspheres to monitor overall EGF
incorporation and release, 55  3% of the EGF present
in the microspheres became incorporated into the scaf-
folds to provide 0.8 g EGF/scaffold. These scaffolds
were then incubated in PBS, and the release of EGF was
monitored over the course of 35 days. The release pro-
file was characterized by an initial burst in which about
50% of the incorporated growth factor was released over
the first 4 days, followed by slow sustained release of
about 0.7% per day (Fig. 1). A similar incorporation ef-
ficiency and release rate were observed for HGF (data
not shown).
Bioactivity of released EGF and HGF
To confirm that incorporated growth factors retained
biological activity after scaffold fabrication, scaffolds
containing either EGF or HGF were incubated with an
appropriate cell type and cell proliferation was moni-
tored. Scaffolds containing approximately 0.8 g EGF
were allowed to release directly into tissue culture
medium over NIH-3T3 cells. The released EGF induced
significant proliferation of the cells as compared to con-
trol cell cultures that were incubated with blank scaffolds
(Fig. 2A). Knowledge of the release kinetics of EGF from
these scaffolds, together with the response of NIH-3T3
cells to known concentrations of EGF (Fig. 2B), revealed
that the released growth factor retained 60–80% of its
bioactivity over this release period. Results obtained by
incubating 4MBr-5 cells with HGF-containing scaffolds
were similar, as the cells demonstrated a significant pro-
liferative response to the released HGF (Fig. 2C). Again,
by comparing the magnitude of the response to values
obtained for known HGF concentrations (Fig. 2D) and
taking into account the HGF release rate, it was deter-
mined that the growth factor also remained between 60
and 80% bioactive for the 15 day release period.
Hepatocyte survival
To determine whether the inclusion of EGF and HGF
would promote the survival of transplanted hepatocytes
beyond 1 week, scaffolds containing VEGF (3.6 g/scaf-
fold) and EGF (1.3 g/scaffold), VEGF and HGF (3.6
g/scaffold), or all three growth factors were seeded with
hepatocytes and transplanted subcutaneously in SCID
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mice for 3, 7, or 14 days. The seeding efficiency of he-
patocytes was determined to be 62  5%. Observation of
H&E-stained tissue sections indicated that a majority of
the transplanted hepatocytes had survived the initial 3
days in vivo, and differences between conditions were not
apparent (Fig. 3A and B). After 7 days, hepatocytes
delivered in scaffolds containing any combination of
growth factors demonstrated enhanced survival as com-
pared to those delivered in blank scaffolds (Fig. 3C and
D). In samples containing no growth factor, the overall
number of hepatocytes had decreased, and many of the
remaining cells lacked evidence of a nucleus, indicating
death. In contrast, the hepatocytes in growth factor-re-
leasing scaffolds appeared similar to those at day 3 with
respect to overall number and morphology. However, dif-
ferences in growth factor combinations did not have an
obvious effect on hepatocyte survival at this point. The
addition of EGF and/or HGF to the delivery system did
not lead to long-term transplanted hepatocyte survival, as
by day 14 the vast majority of hepatocytes remaining in
scaffolds from all conditions were dead (Fig. 3 E and F).
Quantification of hepatocyte survival confirmed the
observed trends, as there was no measurable difference
between any of the conditions at day 3, where approxi-
mately 70% of cells in blank and growth factor–contain-
ing scaffolds remained alive. To clearly illustrate the
trend for hepatocyte survival over the course of the im-
plant study, the numbers of living hepatocytes have been
normalized to the number living at day 3 (Fig. 4). The
number of hepatocytes surviving in conditions including
growth factors remained nearly constant from days 3 to
7, with no significant difference between growth factor
combinations. Survival of the cells transplanted in blank
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FIG. 4. Quantification of hepatocyte survival following trans-
plantation. Hepatocytes were counted in histological sections at
200  magnification after 3, 7, and 14 days in vivo. Data pre-
sented are normalized to the number of live cells present in each
condition at day 3. Results are expressed as mean values and
SEM with n  4.
scaffolds declined to less than 50% of the day 3 value
during the same time interval. However, there was a dra-
matic decrease in hepatocyte survival from days 7 to 14
in all conditions, with the number of surviving cells at
10–20% of day 3 values.
Implant vascularization
The extent of vascularization within scaffolds from all
conditions was assessed at 7 and 14 days to determine
whether the addition of EGF and/or HGF to the delivery
system had an effect on previously observed vascular-
ization induced by VEGF alone.3 Scaffold sections were
immunostained with antibodies against CD31 for identi-
fication of endothelial cells present in blood vessels. Mi-
croscopic visualization of the tissues revealed that a
greater blood vessel density was present in growth fac-
tor-containing scaffolds than in blank scaffolds at both
time points (Fig. 5). There was no observable difference
between the different growth factor combinations, and in
these conditions the enhanced vascularity was more pro-
nounced at day 7 than at day 14. Quantification confirmed
these observations, as the values of vessel density for
growth factor-releasing scaffolds were almost an order of
magnitude greater than those for blank scaffolds at day
7, with no significant difference between the different
growth factor combinations (Fig. 6). At 14 days, the three
growth factor conditions were again similar to each other,
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FIG. 5. Growth factor delivery enhances blood vessel formation. Blood vessels were identified in tissue sections from implanted
scaffolds immunostained for mouse CD31 antigen. Experimental conditions not shown (VEGF  EGF and VEGF  HGF) were
similar in appearance to the condition including all three factors. Note that hepatocytes present in the scaffolds are visible as
large, round cells. original magnification  400
and had over twice the number of blood vessels as con-
trol scaffolds without growth factor. Qualitative differ-
ences in vessel diameter and maturity were not observed
between conditions containing VEGF alone and those
containing EGF and/or HGF, in addition to VEGF.
DISCUSSION
In this investigation, scaffolds previously developed to
deliver a single growth factor (VEGF) were modified to
deliver additionally bioactive EGF and/or HGF in a sus-
tained manner. However, inclusion of these hepatotrophic
factors in the system did not enhance long-term hepato-
cyte survival as anticipated. The transient improvement
in hepatocyte survival observed at the 1 week time point
was expected from previous work and is likely attributed
to VEGF-induced vascularization of the implants, which
was not affected by the presence of EGF or HGF.
Time-appropriate release of bioactive EGF and HGF
was achieved via the methods developed for incorporat-
ing these growth factors into scaffolds. The delivery sys-
tem described in this report was optimized to provide sus-
tained release of both EGF and HGF throughout the 2
week implant studies, such that a significant portion of
the included growth factors were released in a sustained
manner over this time period. Different methods of in-
corporating the two growth factors were required to
achieve similar release kinetics for each. This was ex-
pected, and is likely due to significant differences in the
molecular weights of EGF (6 kDa) and HGF (80 kDa)
since smaller molecules are able to diffuse out of the scaf-
folds more quickly. Thus, EGF was first incorporated into
PLG microspheres used for scaffold fabrication, as this
method has previously been shown to greatly attenuate
protein release from this system.23 The adaptability of
this scaffold system for independently controlled release
of multiple factors and delivery of a variety of cell types
suggest that it will find utility in future tissue engineer-
ing applications.
Long-term hepatocyte survival was not enhanced when
the cells were transplanted on scaffolds containing EGF
and/or HGF, in addition to VEGF. The trend observed at
the earlier time points was similar to that previously ob-
served for delivery of VEGF alone: approximately 70%
of the transplanted hepatocytes survived until day 3, with
no significant decline in survival by day 7 for conditions
where VEGF was included to enhance implant vascular-
ization. This trend was not surprising since these survival
rates are already quite high and would have been diffi-
cult to improve upon with the addition of EGF and HGF.
Inclusion of these hepatotrophic factors also did not ap-
pear to provide longer-term benefit to the transplanted
hepatocytes, as the number of surviving cells declined to
the level observed in blank scaffolds after 14 days in vivo.
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This result was surprising, as other experimental models
in which transplanted hepatocytes have been provided
with EGF or HGF have demonstrated that these factors
do enhance survival of the transplanted cells.4,15,16 An
important difference between these other models of he-
patocyte transplantation and the model employed here is
the location chosen for delivery of the cell population.
Scaffolds containing hepatocytes have most often been
transplanted to the mesentery of the small intes-
tine,2,4–6,15,16 instead of to a subcutaneous site. One pre-
vious study suggested that EGF delivery only enhanced
transplanted hepatocyte survival when an appropriate
background of soluble signals existed at the transplant
site.4 Together with these previous investigations, the re-
sults presented here suggest that a mesenteric site is su-
perior to a subcutaneous one for applications of hepato-
cyte transplantation, perhaps because the vasculature in
this area carries nutrient-rich blood that supplies a better
approximation of the soluble signals present in the liver.
Other potential reasons for the failure of this system
to prolong hepatocyte survival might be that insufficient
quantities of EGF and HGF were delivered to the cells,
or that the factors were delivered with inappropriate re-
lease kinetics. Growth factor release kinetics may have
been affected by the use of Matrigel for in vivo experi-
ments. However, the potential effect of Matrigel is likely
small, as a comparison of studies where VEGF has been
delivered using this system with and without the inclu-
sion of Matrigel does not reveal a significant effect on
the speed or extent of induced vascularization.3,23 There
is a possibility that EGF and HGF interact in a negative
fashion to reduce their bioactivities when simultaneously
released, although this seems unlikely. The factors are
present in low quantities in the scaffolds (0.03 wt%
each) and are known to have an additive effect on hepa-
tocyte proliferation. In addition, previous work with this
delivery system has indicated that multiple factors are
able to retain bioactivity in vivo when simultaneously re-
leased from a single scaffold.23
The blood vessel density present in scaffolds at 7 and
14 days was significantly enhanced with delivery of
VEGF and EGF and/or HGF as compared to control scaf-
folds containing no growth factor. However, there was
no measurable difference among the growth factor-con-
taining conditions, and the inclusion of EGF and/or HGF
did not significantly alter the extent of vascularization in-
duced by VEGF alone.3 It was anticipated that these
growth factors would further enhance the VEGF re-
sponse, as they have also been implicated as promoters
of angiogenesis.24–27 One of the mechanisms by which
HGF promotes angiogenesis is to induce VEGF produc-
tion by a variety of cell types.28–30 The VEGF delivered
from the scaffolds may have already saturated the local
environment, minimizing any effect due to enhanced cell
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FIG. 6. Blood vessel density in scaffolds utilized for deliv-
ery of hepatocytes and combinations of VEGF, EGF, and HGF.
Blood vessels were manually counted at 200  magnification
in tissue sections stained with antibodies for the presence of
mouse CD31. The number of blood vessels counted in the
growth factor samples was significantly greater than (p  0.05)
that observed in blank scaffolds after both 7 and 14 days. There
was no measurable difference between any of the growth fac-
tor combinations at either time point. Results are expressed as
mean values and SEM (n  3).
secretion of VEGF in the transplant area. An impact of
EGF upon vascularization may not have been realized
since its small size and non-heparin binding character
likely allow it to diffuse away from the implanted con-
struct more rapidly than VEGF or HGF. There were also
no qualitative differences in vessel diameter observed be-
tween conditions containing VEGF alone or in combina-
tion with EGF and/or HGF, indicating that these factors
did not appear to promote vessel maturation over this
timeframe.
The system developed in this work for simultaneous
delivery of multiple factors from a porous polymer scaf-
fold, which may also be utilized for delivery of a cell
population, has potential utility in future investigations
of cell-based therapies. Further studies of transplanted he-
patocyte survival could be performed by implanting the
same constructs to a different location, and alternate or
greater quantities of the same growth factors could be
tested for their ability to enhance survival. The effect of
this system might also be enhanced by altering the re-
lease kinetics of EGF and HGF; for example, a greater
release rate of these factors at later times may better sup-
port long-term survival. If one is interested in determin-
ing the effect of a single or a few factors upon hepato-
cyte survival, subcutaneous transplantation may provide
an appropriately isolated environment. This delivery sys-
tem could also be modified for transplantation of other
cell types by including factors known to promote their
survival and/or differentiation. Overall, the results of this
study confirm that significant obstacles exist for hepato-
cyte transplantation to become a clinically relevant ther-
apy, as suggested by many previous investigations. How-
ever, the delivery system developed here may help to
increase understanding of these obstacles and bring ther-
apeutic transplantation of hepatocytes, or other cell types,
closer to reality.
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